22nd San Diego Biopharma Conference (SABPA 2024)
Join Medicilon at the 22nd San Diego Biopharma Conference in the beautiful San Diego. This time, you can not only visit our table, but also focus the speech “Challenges of ADC Preclinical DMPK and Safety Evaluation” by President of Medicilon USA Corp., Dr. Qingcong Lin.
Date: October 5, 2024, 9:00 am - 5:00 pm
Location: Hilton San Diego/Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014
Agenda
About 22nd San Diego Biopharma Conference
The SABPA San Diego BioPharma Conference promises to be a groundbreaking event in the field of biotechnology and pharmaceuticals. The conference will bring together both academia and industry leaders, researchers, and visionaries from around the world to share their insights, latest discoveries and innovations.
This gathering brings together exceptional experts and leaders in both academia and industry to explore the latest breakthroughs, innovations, and opportunities in the field. The conference program boasts a notable lineup of top-level executives, distinguished scientists, and successful entrepreneurs. Topics include in vivo cell engineering and gene editing, protein homeostasis in neurodegeneration, histidine phosphorylation in cancer therapy, the establishment of biotech start-ups within venture-funded incubators and more. This event presents a unique opportunity to acquire knowledge, expand professional networks, and actively contribute to the ongoing transformation within the bio-pharmaceutical industry.
About Medicilon
Medicilon is a leading global integrated pharmaceutical R&D service contract research organization (CRO), providing a full range of one-stop preclinical R&D services, in compliance with Chinese and international regulatory filing standards, to pharmaceutical companies and research institutions world-wide. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry.
20 Years of Excellence
500+ IND Approved by FDA, NMPA, EMA, and TGA
2000+ Active Clients Worldwide
2600+ Scientists & Research Staff
85,000+ m2 Lab Space
At Medicilon, we are dedicated to support our clients develop their research and discovery programs from initial concept through the IND filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.
Services and Solutions
Drug Discovery
❖Chemistry
❖Biology
❖Early DMPK
CMC Services
❖DS/API/DP
❖CMC Research
Preclinical Research
❖Pharmacology
❖Pharmacodynamics
❖Pharmacokinetics
❖Drug Safety Evaluation
❖Bioanalysis
One-stop Integrated Services Platform
❖ADC R&D Service Platform
❖Antibody R&D Service Platform
❖PROTAC R&D Service Platform
❖Cell & Gene Therapy R&D Service Platform
❖Nucleic Acid Drugs R&D Service Platform
❖Peptide Drug Conjugate (PDC) R&D Service Platform
❖Synthetic Biology——Enzyme Catalytic Platform
❖Synthesis Biology——Peptide Drug Discovery Service Platform
❖NanoString nCounter Detection Platform
❖Flow Cytometry Technology Platform
❖Drug Routes of Administration Platform
❖Ophthalmology Platform
❖Inhalation drug R&D platform
❖Skin Topical Preparation R&D Platform
❖Preclinical Tumor Pharmacodynamic Services Platform
❖Preclinical Large Animal Pharmacodynamic Research Service Platform
❖Preclinical Non-tumor Pharmacodynamic Services Platform
……
#SABPA #Medicilon #Drugdiscovery #Preclinical
Share：
Online registrationRelevant
news
marketing@medicilon.com
